Ionis Pharmaceuticals (IONS) Non-Current Deffered Revenue (2009 - 2026)
Ionis Pharmaceuticals (IONS) posted quarterly Non-Current Deffered Revenue of $63.0 million for Q2 2026, down 49.61% year-over-year from $125.1 million in Q2 2025, and down 16.79% quarter-over-quarter from $75.7 million in Q1 2026.
Ionis Pharmaceuticals (IONS) Non-Current Deffered Revenue (2009 - 2026) Analysis & Trends
Ionis Pharmaceuticals' Non-Current Deffered Revenue history runs 18 years deep, the most recent figure standing at $63.0 million for Q2 2026.
- In Q2 2026, Non-Current Deffered Revenue fell 49.61% year-over-year to $63.0 million; the TTM figure through Jun 2026 stood at $63.0 million (down 49.61% YoY), while the FY2025 annual figure was $92.0 million, down 41.21% from the prior year.
- Non-Current Deffered Revenue for Q2 2026 stood at $63.0 million, down from $75.7 million in the prior quarter.
- The five-year high for Non-Current Deffered Revenue was $333.1 million in Q1 2022, with the low at $63.0 million in Q2 2026.
- The 5-year median for Non-Current Deffered Revenue is $201.9 million (2024), against an average of $199.3 million.
- The sharpest annual moves came in 2023 and 2026: Non-Current Deffered Revenue decreased 15.4% in 2023, then sank 49.61% in 2026.
- Ionis Pharmaceuticals' Non-Current Deffered Revenue stood at $287.8 million in 2022, then declined by 16.19% to $241.2 million in 2023, then plunged by 35.11% to $156.5 million in 2024, then sank by 41.21% to $92.0 million in 2025, then plunged by 31.49% to $63.0 million in 2026.
- Business Quant data shows IONS's Non-Current Deffered Revenue at $63.0 million in Q2 2026, $75.7 million in Q1 2026, and $92.0 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Deffered Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 220.40 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | - |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | - |
| 10 | Ionis Pharmaceuticals | 9.48 Bn | 7.43 Bn | 265.21 Mn | 63.03 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 63.03 Mn |
| Mar 31, 2026 | 75.75 Mn |
| Dec 31, 2025 | 92.00 Mn |
| Sep 30, 2025 | 107.91 Mn |
| Jun 30, 2025 | 125.10 Mn |
| Mar 31, 2025 | 140.68 Mn |
| Dec 31, 2024 | 156.50 Mn |
| Sep 30, 2024 | 173.78 Mn |
| Jun 30, 2024 | 188.70 Mn |
| Mar 31, 2024 | 215.09 Mn |
| Dec 31, 2023 | 241.18 Mn |
| Sep 30, 2023 | 249.27 Mn |
| Jun 30, 2023 | 254.40 Mn |
| Mar 31, 2023 | 272.97 Mn |
| Dec 31, 2022 | 287.77 Mn |
| Sep 30, 2022 | 294.66 Mn |
| Jun 30, 2022 | 315.20 Mn |
| Mar 31, 2022 | 333.14 Mn |
| Dec 31, 2021 | 351.88 Mn |
| Sep 30, 2021 | 362.89 Mn |